Jagsonpal Pharmaceuticals Ltd disclosed that it has received a tax demand order of ₹48.2 million from the Income Tax Department’s Faceless Assessment Unit for AY 2024–25. The demand arose from disallowed expenses in its tax filings. The company plans to appeal and expects no material impact on operations.
Introduction To The Announcement
On March 13, 2026, Jagsonpal Pharmaceuticals Ltd informed stock exchanges that the Income Tax Department issued a demand order of ₹48.2 million. The company confirmed it will challenge the order before the appellate authority within the prescribed timelines.
Tax Demand Details
-
Authority: Income Tax Department, Faceless Assessment Unit
-
Amount: ₹48.2 million (₹4.82 crore)
-
Assessment Year: 2024–25
-
Reason: Disallowed expenses in tax filings
-
Status: Company to file appeal with appellate authority
Strategic Importance
Jagsonpal’s proactive disclosure demonstrates transparency and compliance with SEBI’s Listing Obligations and Disclosure Requirements. The company emphasized that the demand will not materially affect its financials or operations, reassuring investors of its governance standards.
Broader Implications
Tax demands of this nature are part of routine regulatory oversight. By appealing, Jagsonpal aims to safeguard shareholder interests while continuing to focus on its pharmaceutical business growth.
Key Highlights
• Jagsonpal Pharmaceuticals receives tax demand of ₹48.2 million
• Demand relates to AY 2024–25 from Income Tax Department
• Company plans to appeal against the order
• No material impact expected on financials or operations
• Disclosure made under SEBI LODR regulations
Sources: BSE Corporate Filings, ScanX News, Economic Times